...
首页> 外文期刊>HPB: the official journal of the International Hepato Pancreato Biliary Association >Multicentre study of liver metastases from colorectal cancer in pathological livers.
【24h】

Multicentre study of liver metastases from colorectal cancer in pathological livers.

机译:病理肝脏中大肠癌肝转移的多中心研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVES: Resection of colorectal cancer (CRC) liver metastases (LM) in pathological liver (PL) patients (with cirrhosis or hepatopathy) is extremely rare. The aim of this study was to perform a multicentre, retrospective analysis of epidemiology, surgical techniques and outcomes in patients with PL who underwent hepatic resection for CRC-LM. METHODS: A retrospective, multicentre questionnaire was distributed to 15 hepatopancreatobiliary surgical units. RESULTS: Only six of 15 (40%) HPB units reported any experience in the surgical resection of CRC-LM in patients with PL. Of the 20 patients identified, 10 had underlying cirrhosis and 10 had chronic hepatopathy. Their median age was 66 years (range: 49-81 years). Thirteen patients were male. Liver dysfunction was known preoperatively in 18 patients. All patients had Child-Pugh class A disease. Six patients had synchronous disease. There were a total of 38 lesions among the 20 patients, distributed at a median of one lesion per patient (range: 1-4 lesions). The median size of the lesions was 3.0 cm (range: 1.5-9.0 cm). Preoperative median carcinoembryonic antigen (CEA) was 32.3 ng/ml (range: 1-184 ng/ml). The surgical procedures performed included: sub-segmentectomy (n= 12); left lateral sectionectomy (n= 6); segmentectomy (n= 4); radiofrequency ablation (n= 3), and exploratory laparotomy (n= 4). Morbidity occurred in four patients (Clavien grades I [n= 1], II [n= 2] and IVa [n= 1]). Mortality was nil. An R0 resection margin was achieved in 15 of 16 patients. Twelve patients did not receive chemotherapy. In resected patients, 10 presented with relapse. The median disease-free and overall survival periods were 12.2 and 22.3 months, respectively. CONCLUSIONS: When feasible, liver resection is the best option for CRC-LM in PL patients.
机译:目的:在病理性肝病(肝硬化或肝病)患者中,结直肠癌(CRC)肝转移瘤(LM)的切除极为罕见。本研究的目的是对接受CRC-LM肝切除的PL患者进行流行病学,手术技术和结局的多中心,回顾性分析。方法:向15个肝胰胆管外科手术单位分发了一项回顾性的多中心问卷。结果:15名HPB单位中只有6名(占40%)报告了PL患者进行CRC-LM手术切除的任何经验。在确定的20位患者中,有10位患有基础肝硬化,有10位患有慢性肝病。他们的中位年龄为66岁(范围:49-81岁)。男性十三例。术前已知肝功能异常的患者有18例。所有患者均患有Child-Pugh A类疾病。六例患者患有同步疾病。 20名患者中共有38个病灶,平均分布为每名患者1个病灶(范围:1-4个病灶)。病变的中位大小为3.0厘米(范围:1.5-9.0厘米)。术前癌胚抗原(CEA)为32.3 ng / ml(范围:1-184 ng / ml)。所执行的手术程序包括:节段切除术(n = 12);左侧切面切除术(n = 6);节段切除术(n = 4);射频消融(n = 3)和探查性剖腹术(n = 4)。四例患者发生了发病(Clavien等级I [n = 1],II [n = 2]和IVa [n = 1])。死亡率为零。 16例患者中有15例达到了R0切除切缘。 12名患者未接受化学疗法。在切除的患者中,有10例复发。中位无病生存期和总生存期分别为12.2和22.3个月。结论:在可行的情况下,肝切除是PL患者CRC-LM的最佳选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号